Table 1

Baseline Patient and Procedure Characteristics of the 3 Study Groups

Roll-In (n = 87)VCD (n = 267)MC (n = 134)
Patient characteristics
  Age, yrs63.3 ± 11.663.3 ± 11.161.4 ± 10.5
  Women, n (%)29 (33)85 (32)51 (38)
  Body mass index 30 kg/m2, n (%)41 (47.1)100 (37.4)45 (33.6)
  Baseline hematocrit, %40.4 ± 4.241.4 ± 2.040.5 ± 4.4
 History of: n (%) of patients
  Percutaneous coronary intervention37 (42.5)110 (41.2)61 (45.5)
  Coronary artery bypass graft16 (18.4)45 (16.9)24 (17.9)
  Peripheral vascular surgery or graft4 (4.6)8 (3.0)1 (0.8)
  Hyperlipidemia70 (80.5)211 (79.0)117 (87.3)
  Hypertension70 (80.5)206 (77.2)98 (73.1)
  Diabetes21 (24.1)68 (25.5)44 (32.8)
  Renal insufficiency7 (8.1)23 (8.6)9 (6.7)
  Smoking39 (44.8)152 (57.1)66 (49.3)
  Systolic blood pressure, mm Hg134 ± 22133 ± 20133 ± 20
Procedure characteristics
 Type of procedure, n (%) of patients
  Diagnostic58 (66.7)134 (50.2)66 (49.3)
  Interventional29 (33.3)133 (49.8)68 (50.8)
 Antithrombotic treatment, n (%) of patients
  Abciximab2 (2.3)10 (7.5)4 (5.9)
  Aspirin2 (2.3)7 (5.3)3 (4.4)
  Clopidogrel7 (8.0)28 (21.1)12 (17.6)
  Eptifibatide9 (10.3)27 (10.1)11 (8.2)
  Heparin37 (42.5)136 (50.9)68 (50.7)
 Activated clotting time, s168 ± 55181 ± 56142 ± 34

Unless specified otherwise, values are mean ± SD.

  • Immediately before sheath removal;

  • among patients who underwent diagnostic procedures, none received abciximab or clopidogrel, and 1 patient each in the manual compression (MC) and vessel closure device (VCD) groups received eptifibatide;

  • p < 0.0001 versus VCD; all other differences between the 2 randomly assigned groups are statistically nonsignificant.